The European Crohn’s and Colitis Organization (ECCO) also recommends the use of anti-TNF as the first-line therapy in moderate-to-severe Crohn’s disease while reserving the use of vedolizumab in patients with inadequate response to anti-TNF therapy [4]. This evidence concerns the gene TNF and colitis.